The Summary
A large retrospective study analyzed insurance claims from over 21,000 US adults with overweight/obesity and established heart disease, but without diabetes. After matching patients based on baseline characteristics, researchers compared those newly prescribed semaglutide to those on tirzepatide. The study found that the semaglutide group had a 29% lower risk of a major cardiovascular event (heart attack, stroke, or death) and a 22% lower risk of an expanded list of heart events compared to the tirzepatide group, suggesting superior cardiovascular protection in this population.
Why this is interesting
Both semaglutide and tirzepatide are blockbuster drugs for weight loss known to benefit the heart. This is one of the first large, real-world studies directly comparing their cardiovascular outcomes in people with obesity but not diabetes. The results suggest semaglutide may have a significant edge in protecting these high-risk individuals from future heart attacks and strokes. For patients with existing heart disease, this finding provides crucial information to discuss with their doctor when choosing between these powerful medications.